A promising area of research for laboratory diagnosis of AD is the analysis of cerebrospinal fluid (CSF), where the measurement of beta-amyloid (Aβ) with 40 or 42 amino acids, total tau, and phospho-tau-181 can distinguish patients with AD from healthy subjects with high specificity and sensitivity (Blennow, 2005; Blennow et al., 2010; Humpel, 2011). Here, MAPT is linked to Alzheimer disease.